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Abstract 24 
Prenatal hyperandrogenism is hypothesized as one of the main factors contributing to 25 
the development of polycystic ovary syndrome (PCOS). PCOS patients have high risk 26 
of developing fatty liver and steatosis. This study aimed to evaluate the role of prenatal 27 
hyperandrogenism in liver lipid metabolism and fatty liver development. Pregnant rats 28 
were hyperandrogenized with testosterone. At pubertal age, the prenatally 29 
hyperandrogenized (PH) female offspring displayed both ovulatory (PHov) and 30 
anovulatory (PHanov) phenotypes that mimic human PCOS features. We evaluated 31 
hepatic transferases, liver lipid content, the balance between lipogenesis and fatty acid 32 
oxidation pathway, oxidant/antioxidant balance and pro-inflammatory status. We also 33 
evaluated the general metabolic status through growth rate curve, basal glucose and 34 
insulin levels, glucose tolerance test, HOMA-IR index and serum lipid profile. 35 
Although neither PH group showed signs of liver lipid content, the lipogenesis and fatty 36 
oxidation pathways were altered. The PH groups also showed impaired 37 
oxidant/antioxidant balance, a decrease in the pro-inflammatory pathway (measured by 38 
prostaglandin E2 and cyclooxygenase-2 levels), decreased glucose tolerance, imbalance 39 
of circulating lipids and increased risk of metabolic syndrome. We conclude that 40 
prenatal hyperandrogenism generates both PHov and PHanov phenotypes with signs of 41 
liver alterations, imbalance in lipid metabolism and increased risk of developing 42 
metabolic syndrome. The anovulatory phenotype showed more alterations in liver 43 
lipogenesis and a more impaired balance of insulin and glucose metabolism, being more 44 
susceptible to the development of steatosis. 45 
 46 
 47 
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Introduction 48 
Polycystic ovary syndrome (PCOS) is one of the most common endocrine and 49 
metabolic disorders that affect women in their reproductive age (Franks 2003) and its 50 
clinical manifestations often emerge during puberty (Rosenfield 2007; Yan, et al. 2013).  51 
PCOS etiology remains controversial and current theories emphasize on genetic and 52 
intrauterine origins coupled with environmental factors such as the diet and altered 53 
lifestyle patterns (Franks 1995). It has been reported that prenatal androgen exposure is 54 
able to induce polycystic ovaries in rats (Demissie, et al. 2008; Foecking, et al. 2008), 55 
monkeys (Abbott, et al. 2010) and sheep (Manikkam, et al. 2006) and that fetal 56 
programming, mediated by prenatal hyperandrogenism, is related to hyperinsulinemia, 57 
dyslipidemia, insulin resistance (IR), cardiovascular disease and metabolic syndrome 58 
(Amalfi, et al. 2012; Demissie et al. 2008; Heber, et al. 2013). However, how fetal 59 
programming impacts on different tissues is unknown.   60 
The liver is involved in lipid synthesis, transportation and storage, as well as in glucose 61 
and insulin metabolism (Paschos and Paletas 2009), all key factors in PCOS 62 
pathogenesis (Baranova, et al. 2011; den Boer, et al. 2004; Paschos and Paletas 2009; 63 
Vassilatou 2014). One of the most frequent hepatic affections, related to metabolic 64 
abnormalities, is non-alcoholic fatty liver disease (NAFLD),which affects 20%-30% of 65 
the general population (Vassilatou 2014). NAFLD includes a clinicopathologic 66 
spectrum of conditions that encompass from simple steatosis (triglyceride (TG) 67 
accumulation in hepatocytes) to steatohepatitis with inflammation, fibrosis and even 68 
cirrhosis (Browning and Horton 2004). NAFLD pathogenesis remains unknown and 69 
there are many hypotheses about its origin (Lee, et al. 2014; Yasui, et al. 2012). 70 
Currently, the most accepted model proposes a multiple and parallel hits hypothesis. 71 
Page 3 of 35
4 
 
Fatty acids and their metabolites are the lipotoxic agents involved in NAFLD 72 
development (Day and James 1998; Lin, et al. 2014), being the increase in oxidative 73 
stress one of the key factors in NAFLD pathogenesis (Lin et al. 2014; Madan, et al. 74 
2006). 75 
In physiological conditions, in the liver, there is an equilibrium between the uptake and 76 
exportation of fatty acids (which in turn can be esterified or to be oxidized) (Browning 77 
and Horton 2004; Kawano and Cohen 2013). However, when the balance between 78 
lipolysis and lipogenesis is altered, or fatty acid influx to the liver is increased, lipid 79 
droplets could accumulate in the liver, leading to steatosis and even NAFLD (den Boer 80 
et al. 2004; Kawano and Cohen 2013). 81 
A common feature of NAFLD and PCOS is IR (Gambarin-Gelwan, et al. 2007; 82 
Schwimmer, et al. 2005). However, it remains controversial whether IR is the key cause 83 
in the development of NAFLD in women with PCOS (Gambarin-Gelwan et al. 2007; 84 
Liang and Ward 2006). Since PCOS patients with hyperandrogenic phenotypes have a 85 
higher prevalence of developing NAFLD, it has been suggested that androgens could 86 
contribute to the development of the pathology (Vassilatou 2014; Vassilatou, et al. 87 
2010). We have previously demonstrated that the levels of androgen administered in 88 
pregnant rats are directly related to the PCOS-like phenotype displayed in the female 89 
offspring during the pubertal age (Amalfi et al. 2012) and that the fetal programming 90 
generated by androgens leads to metabolic alterations, particularly in lipid metabolism, 91 
which worsen through life (Heber et al. 2013).  92 
Based on the above, the aim of this study was to evaluate the effect of prenatal 93 
hyperandrogenism on the liver function and lipid metabolism.  94 
 95 
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Materials and methods 96 
 Animals and treatments 97 
Virgin female rats of the Sprague Dawley strain were mated with fertile males of the 98 
same strain. Three females and one male were housed in each cage under controlled 99 
conditions of light (12 h light, 12 h dark) and temperature (23-25 ºC). Animals received 100 
food and water ad libitum. Day 1 of pregnancy was defined as the morning on which 101 
spermatozoa were observed in the vaginal fluid. As previously described (Demissie et 102 
al. 2008), pregnant rats (N=15) received subcutaneous injections of 1 mg of free 103 
testosterone (T-1500; Sigma, St. Louis, MO, USA) dissolved in 100 µl sesame oil from 104 
day 16 to day 19 of pregnancy. This hormonal paradigm mimics the fetal testosterone 105 
surge that is observed in male rats when the reproductive axis in the fetus is established. 106 
Another group (N=15) received only 100 µl of sesame oil. The dose was selected based 107 
on previous findings of our lab (data not published) and other studies which have shown 108 
that this dose leads to ovulatory and anovulatory phenotypes and that higher doses lead 109 
only to anovulatory phenotypes during the adult life and even to vaginal atresia (Wolf, 110 
et al. 2002). Under the conditions of our animal facilities, spontaneous term labor 111 
occurs on day 22 of gestation. Female offspring were separated from males at 21 days 112 
of age and sacrificed during pubertal age at 60 days of age. Those from 113 
hyperandrogenized mothers were the prenatally hyperandrogenized (PH) group and 114 
those from mothers injected with sesame oil were the control (Ctl) group. Animals were 115 
allowed free access to Purina rat chow (Cooperación SRL, Argentina) and water. All the 116 
procedures involving animals were conducted in accordance with the Animal Care and 117 
Use Committee of Consejo Nacional de Investigaciones Científicas y Tecnicas 118 
(CONICET) 1996, Argentina, and the study was approved by the Ethics Committee of 119 
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the School of Medicine of University of Buenos Aires. To establish the phenotype 120 
diversity, the above procedures were independently repeated three times.   121 
At 60 days of age, 75 female offspring from each group were anesthetized with carbon 122 
dioxide and killed by decapitation. Trunk blood was collected and serum was separated 123 
and kept at -80°C for further studies. Ovaries and liver were extracted and conserved at 124 
-80°C or fixed in 4% (v/v) formaldehyde for histological studies. All animals were 125 
randomly assigned for each assay. 126 
Characterization of the prenatally hyperandrogenized murine model  127 
 Serum testosterone was quantified from 15 offspring from each group by 128 
radioimmunoassay (RIA) as previously described (Amalfi et al. 2012). Serum estradiol 129 
levels were quantified by Cobase immunoassay analyzers using an Electro 130 
Chemiluminescence Immuno Assay (ECLIA) following the manufacturer’s instructions. 131 
The intra- and interassay coefficients of variation (CVs) were 7.3% and 13.2% 132 
respectively for testosterone and 3.93% and 7.08% respectively for estradiol.  133 
The estrous cycle was determined by vaginal smears taken daily from 45 to 60 days of 134 
age in all the animals. 135 
Regular ovulatory animals were those that showed smears displaying the four stages of 136 
the estrous cycle in the following order: proestrus, estrus, metaestrus, diestrus, with 137 
cycles of 4 to 6 days. Irregular ovulatory animals were both those that showed some 138 
smears displaying an estrous stage but further smears not following the progress of the 139 
cycle as described above, and those whose cycles lasted 7 days or more (PHov). 140 
Anovulatory animals were whose smears showed metaestrus, diestrus, or a combination 141 
of both for four consecutive days, and were thus considered to be non-cycling (PHanov) 142 
(Karim, et al. 2003). 143 
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To evaluate ovarian histology, 10 ovaries from each group were removed and 144 
immediately fixed in 4% (v/v) formaldehyde and analyzed by two different 145 
investigators. Ovaries were embedded in paraffin wax and consecutively cut. To prevent 146 
counting the same follicle twice, 6-µm step sections were mounted at 50-µm intervals 147 
onto microscope slides. Then, slides were stained with hematoxylin and eosin 148 
(Woodruff, et al. 1990). 149 
Hepatic enzymes  150 
Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 151 
gamma-glutamyl transferase (GGT) were quantified by colorimetric enzymatic methods 152 
(Wiener Lab, Argentina) following the manufacturer´s instructions. The chromophoric 153 
products were measured at 340 nm for ALT and AST and at 405 nm for GGT, all at 154 
25°C. The intra- and interassay Cvs were 3.02% and 5.63% for ALT, 4.4% and 4.9% 155 
for AST, and 1.62% and 5% for GGT.  156 
Liver lipid and TG content 157 
Fragments of hepatic tissue randomly selected from 15 female offspring from each 158 
group were fixed in formaldehyde 4% (v/v), cut in cryostat and stained with SUDAN IV 159 
to visualize lipid droplets using hematoxylin as contrast stain. The intestine of tadpole 160 
was used as a positive control of the SUDAN IV technique (Regueira, et al. 2016).  To 161 
evaluate the TG content in the liver, 15 frozen samples of  each  group were saponified 162 
and TG content was quantified by comparing to a glycerol standard curve by a 163 
commercial kit (Wiener Lab, Argentina), as previously described (Chow, et al. 2011).  164 
Hepatic lipid metabolism 165 
The mRNA expression of Acetyl-CoA carboxylase (ACC) 1 and2 (Acaca and Acacb, 166 
respectively), Fatty acid Synthase (Fas), stearoyl-CoA desaturase (Scd1), Sterol 167 
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regulatory element-binding protein1 (Srebp1), carbohydrate response element binding 168 
protein (Chrebp), Peroxisome proliferator-activated receptor alpha and gamma 169 
(Pparalpha and Ppargamma) and PPARgamma co-activator 1alpha (Pgc1a) was 170 
evaluated by Real-Time PCR analysis in 15 different samples from each group. Total 171 
mRNA from hepatic tissue was extracted using RNAzol RT (MRC gene, Molecular 172 
Research Center, Cincinnati, OH, USA) following the manufacturer’s instructions. 173 
cDNA was synthesized from 500 ng mRNA by using random  primers. Real-Time PCR 174 
analysis was performed from this cDNA by means of the real mix B124-100 175 
(Biodynamics SRL, USA). The amplified products were quantified by fluorescence 176 
using the Rotor Gene 6000 Corbett and mRNA abundance was normalized to the 60s 177 
Ribosomal protein L32 (L32) amount. L32 was validated as a reference gene because 178 
the variance between treatments did not differ. Results are expressed as arbitrary units. 179 
The primers are shown in Table 1. 180 
Liver oxidant/antioxidant balance  181 
The oxidant–antioxidant balance in liver tissue was evaluated as the lipid peroxidation 182 
index and the content of the antioxidant glutathione (GSH) in 15 samples of each group. 183 
The amount of malondialdehyde formed from the breakdown of polyunsaturated fatty 184 
acids is taken as an index of the peroxidation reaction. The method used in this study 185 
was as that previously described (Amalfi et al. 2012; Heber et al. 2013). The reduced 186 
form of GSH, which comprises the bulk of cellular protein sulfhydryl groups, was 187 
quantified as previously described (Amalfi et al. 2012; Heber et al. 2013).  188 
Liver inflammatory status  189 
 The inflammatory status in liver tissue was measured by evaluating the levels of 190 
Prostaglandin E (PGE) and cyclooxygenase-2 (COX2), the limiting enzyme of its 191 
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synthesis. PGE was determined by RIA as previously reported (Motta, et al. 1999). 192 
COX2 was measured by the Western blotting technique, using 200 mg of liver tissue  193 
from 10 independent samples per group, as previously described (Amalfi et al. 2012).  194 
General metabolism imbalance 195 
The body weight of all the animals of all the groups was determined at 21, 28, 38, 45 196 
and 60 days of age. 197 
Basal insulin levels were measured by an ELISA kit, following the manufacturer’s 198 
instructions (Abcam Insulin Human ELISA Kit) and basal glucose levels were 199 
quantified by colorimetric enzymatic methods (Wiener Lab, Argentina) (N=10 per 200 
group). The intra- and interassay Cvs were 10% and 12% respectively for insulin and 201 
1.39% and 1.92% respectively for glucose.  202 
The glucose tolerance test (IPGTT) was performed in separate groups of ten female 203 
offspring from each group, as previously described (Amalfi et al. 2012; Demissie et al. 204 
2008). The homeostatic model assessment for IR (HOMA-IR) was determined (Yan et 205 
al. 2013). The circulating lipid profile was evaluated as previously described and the 206 
TG/HDL cholesterol ratio was taken as a marker of metabolic syndrome risk (Heber et 207 
al. 2013). 208 
Statistical analysis 209 
Statistical analyses were carried out using the Instant program (GraphPad software, San 210 
Diego, CA, USA). ANOVA with post-hoc Tukey test was used to compare the three 211 
treatments. Statistical significance was considered as p<0.05.  212 
 213 
 214 
 215 
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Results  216 
Characterization of the prenatally hyperandrogenized murine model  217 
The PHov and PHanov groups showed higher serum testosterone levels than the control 218 
group, but only PHanov animals displayed lower estradiol levels than the control (Fig. 219 
1A and 1B, p<0.01). Figure 1C shows a representative ovarian tissue section from the 220 
control group. The general appearance of the tissue resembled normal histology: a 221 
central medulla consisting mainly of fibromuscular stroma and corpora lutea and antral 222 
follicles located in the peripheral cortex. Histological examination of ovaries from the 223 
PHov and PHanov groups (Fig. 1C and 1D) revealed the presence of corpora lutea, 224 
cysts and an excess of small antral follicles. In addition, in PHanov animals, the ovary 225 
was disorganized as compared to the control group and small follicles could be seen 226 
invading the central medulla. The detail in figure 1E shows that cysts present a layer of 227 
theca cells and a thin compacted formation of granulosa cells.  228 
Regarding the estrous cycle, in the three independent repetitions of the animal 229 
procedure, always 100% of the control rats showed a regular estrous cycle. Within the 230 
PH group, 43-51% showed irregular estrous cycles and were considered as PHov, 231 
whereas 27-39% presented anovulatory cycles and were considered PHanov. 232 
Testosterone did not affect the age of vaginal opening. 233 
Prenatal hyperandrogenism and hepatic alterations 234 
ALT levels were increased in the PHov group (Fig. 2A, p<0.01). Neither AST or GGT 235 
levels were affected in the PHov or PHanov groups as compared with the control group 236 
(Fig. 2B and 2C respectively, p>0.05).   237 
As compared with the positive control of the SUDAN IV technique (Fig. 2D, arrows), 238 
neither the control group (Fig. 2E) nor the PHov or PHanov phenotypes (Fig. 2F and 239 
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2G) showed hepatic lipid droplets. In addition, no differences were found in the hepatic 240 
TG content between groups (Fig. 2H, p>0.05).  241 
Regarding the transcription factors that are mediators of lipogenesis, we found that 242 
Ppargamma and Srebp mRNA levels were higher in both PH groups than in the control 243 
group (Fig. 3A and 3B, p<0.05), whereas Chrebp levels were only altered in the 244 
PHanov animals (Fig. 3C, p<0.05). Regarding the enzymes involved in lipogenesis, we 245 
found that the mRNA levels of the genes encoding both isoforms of Acetyl-CoA 246 
carboxylase (Acaca and Acacb) were decreased in both PH groups (Fig. 3 D and 3E, 247 
p<0.05). Fas mRNA levels were increased in the PH groups (Fig. 3F, p<0.05), whereas 248 
Scd1 mRNA levels were only impaired in PHanov animals (Fig. 3G, p<0.05). 249 
Regarding fatty acid oxidation pathways, we found that Pparalpha mRNA levels 250 
showed no differences between the control and PHov groups but were decreased in 251 
PHanov (Fig. 3H, p<0.01), and that Pgc1a levels were lower in both PH animals than in 252 
controls (Fig. 3I, p<0.01).  253 
L32 was validated as a reference gene, obtaining no statistical difference in the stability 254 
between treatments measured by the Ct (threshold cycle) (control=21.76 + 0.24; PHov= 255 
21.36 + 0.30; PHanov= 21.70 + 0.34; p=0.67). 256 
The lipid peroxidation index was higher in the PH groups than in the control (Fig. 4A, 257 
p<0.05). GSH levels were altered in both PH groups as compared to the control. GSH 258 
levels were increased in the PHov groups and decreased in the PHanov group (Fig. 4B, 259 
p<0.01).  260 
Both the levels of PGE and the protein expression of COX2 were lower in the PH 261 
groups than in the control group. In addition, the PGE levels were lower in the PHanov 262 
group than in the PHov animals (Fig. 4C and 4D, p<0.01).  263 
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Prenatal hyperandrogenism and metabolic derangements  264 
Prenatal hyperandrogenism did not affect the body weight from prepubertal to pubertal 265 
age (Fig. 5A, p=0.41). Insulin levels were increased in both PH groups as respect to 266 
controls (Fig. 5B, p<0.05), and basal glucose levels were impaired in the PHanov group 267 
(Fig. 5C, p<0.05). The IPGTT showed that prenatal hyperandrogenism induced 268 
increased levels of circulating glucose (Fig. 5D), represented by the area under the 269 
curve of glucose concentration (control = 14873.0 + 119.7; PHov = 21045.0 + 164.0; 270 
PHanov= 2090.0 + 156.6 in arbitrary units, control vs. PHov p<0.01; control vs. 271 
PHanov p<0.05; PHov vs. PHanov p>0.05). The HOMA-IR index was increased in the 272 
PHanov group as compared to controls (Fig. 5E, p<0.05).  273 
Both PH groups showed an altered circulating lipid profile, displaying higher levels of 274 
circulating low-density lipoproein cholesterol (LDL) (Fig. 6A, p<0.05) and TG than the 275 
control group (Fig. 6B, p<0.01). No significant differences were found in the levels of 276 
total cholesterol or high-density lipoprotein (HDL) cholesterol (Fig. 6C and 6D, 277 
p>0.05). The TG/HDL cholesterol ratio, as a marker of metabolic syndrome risk was 278 
higher in both PH groups than in the control group (control=1.13 + 0.34; PHov= 2.42 + 279 
0.24; PHanov= 2.65 + 0.39, p<0.05; PHov vs. control and PHanov vs. control, p>0.05 280 
PHov vs. PHanov).  281 
 282 
Discussion 283 
The developmental origins of PCOS are controversial. Some authors have reported that 284 
an altered in utero environment could be responsible for metabolic diseases and PCOS 285 
features development in different species (Abbott, et al. 2005; Demissie et al. 2008; 286 
Hogg, et al. 2011), whereas others propose PCOS as a multiplicity of etiologies and not 287 
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a simple mechanism and emphasize genotype features (Franks and Berga 2012; 288 
Gluckman and Hanson 2004). It is known that both the embryo development stages and 289 
early postnatal life period are crucial to condition adult health life. Thus, currently used 290 
PCOS animal models focus on these critical development time windows (Abbott et al. 291 
2010; Amalfi et al. 2012; Demissie et al. 2008; Jang, et al. 2015; Manikkam et al. 292 
2006). Furthermore, the metabolic and endocrine alterations found in the prenatal 293 
models lead to several long-term effects, thus highlighting the importance of the in 294 
utero environment.  295 
In the present study, we reproduced a murine model wich displayed PCOS features 296 
leading to two phenotypes: both with hyperandrogenism and ovarian alterations, such as 297 
an increase in the number of preantral follicles and the formation of cysts. Nearly 50% 298 
of the cases of the PH group presented irregular ovulatory estrous cycles whereas 299 
around 40% of the cases in PH group presented the anovulatory phenotype. 300 
Ovaries from PCOS women are known to contain an increased number of small follicles 301 
that have and excessive early growth but with follicular arrest, thus preventing the 302 
selection and further maturation of a dominant follicle. These data are in accordance 303 
with our results showing that androgens play a role in follicle recruitment (Jonard and 304 
Dewailly 2004). 305 
We found that PH rats showed incipient liver damage. These data are in agreement with 306 
previous reports that suggest that the intrauterine environment plays an important role in 307 
the development of both NAFLD and PCOS during postnatal life (Baranova, et al. 308 
2013; Brumbaugh and Friedman 2014).  309 
Contrary to other reports (Demissie et al. 2008; Hogg et al. 2011), we found no lipid 310 
accumulation in the liver. This difference could be due to the higher doses of androgens 311 
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used in those reports and is in agreement with our previous findings where higher doses 312 
of androgens induced a more severe PCOS-like phenotype as well as worse endocrine 313 
and metabolic disturbances (Amalfi et al. 2012). To deepen the study of lipid 314 
metabolism in the liver, we evaluated the status of the de novo lipogenesis pathway and 315 
β-fatty acid oxidation mediators (Figure 7). To assess the lipogenic pathway, we 316 
evaluated the role of three transcription factors involved in the regulation of de novo 317 
lipogenesis. Two of them, Srebp and Chrebp, are regulated by insulin and glucose 318 
levels, respectively, and both regulate the expression of genes encoding lipogenic 319 
enzymes (Browning and Horton 2004; Strable and Ntambi 2010). Our results showed 320 
that the PH groups presented high levels of Srebp, consistent with the high levels of 321 
serum insulin found in PH animals. Moreover, Chrebp was impaired in the PHanov 322 
group, showing a correlation with basal glucose levels in those animals. These data are 323 
in accordance with that described by other authors showing that in the hyperinsulinemic 324 
and even more in the IR states, SREBP1-c transcription is stimulated and could lead to 325 
de novo fatty acid synthesis (Browning and Horton 2004; Strable and Ntambi 2010). 326 
The third transcription factor studied, also involved in the regulation of lipogenesis, was 327 
PPARgamma. It has been shown that in animal models of IR, PPARgamma levels are 328 
increased, promoting lipid storage (Ables 2012; Kawano and Cohen 2013). In 329 
agreement with these data, our results showed increased Pppargamma levels in the PH 330 
groups, thus highlighting the relationship between liver lipid metabolism and glucose 331 
and insulin metabolism. Although only the PHanov phenotype presented signs of IR, by 332 
the HOMA-IR index, both PH groups showed increased insulin levels and decreased 333 
glucose tolerance by the IPGGT test.  334 
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In addition to an altered expression of the transcription factors modulating lipogenic 335 
genes, we found alterations in the mRNA levels of the genes encoding FAS and SCD1, 336 
both enzymes involved in lipogenesis. Both PH groups showed increased levels of Fas 337 
but only the PHanov group showed altered levels of Scd1, the enzyme leading to 338 
monounsaturated fatty acids. Thus, although the lipogenic pathway was altered in both 339 
PH groups, the PHanov showed a deeper dysregulation of the lipogenesis system.   340 
The first limiting factor in lipogenesis is the synthesis of Malonyl-CoA, which is 341 
synthesized by ACC, which is present in both isoforms encoded by the Acaca and 342 
Acacb genes. Our results surprisingly showed that both mRNA levels were decreased in 343 
the PH groups, independently of the increased levels of Srebp, Chrebp and Ppargamma. 344 
Malonyl-CoA is an indirect inhibitor of fatty acid oxidation (Browning and Horton 345 
2004) and it has been described that when one of the ACC isoforms is reduced, fatty 346 
acid oxidation results increased. These findings suggest that the reduction of Acaca and 347 
Acacb expression could be due to the effect of other regulatory mechanisms 348 
(independently of Ppargamma, Srebp and Chrebp action), which may be preventing 349 
lipid accumulation by decreasing Malonyl-CoA synthesis (Savage, et al. 2006; Strable 350 
and Ntambi 2010), thus  favoring fatty acid oxidation.    351 
Our results are in accordance with other studies (Mao, et al. 2006; Strable and Ntambi 352 
2010) that show that Acaca levels are independent of the expression of the genes 353 
involved in fatty acid synthesis. In fact, the knock-out of Acaca shows increased levels 354 
of several genes that encode proteins involved in lipogenesis but without hepatic lipid 355 
accumulation (Mao, et al. 2006; Strable and Ntambi 2010). These data demonstrate that 356 
Acaca could be playing a protective role in the development of hepatic steatosis.     357 
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In addition to the alterations found in the lipogenesis pathways, we found derangements 358 
in fatty acid oxidation (Fig. 7). By having opposite functions, Pparalpha and 359 
Ppargamma regulate fat metabolism and while Ppargamma promotes lipid storage, 360 
Pparalpha promotes lipid utilization (Ables 2012; Kawano and Cohen 2013; Souza-361 
Mello 2015). In the present study, prenatal hyperandrogenization decreased Pparalpha 362 
levels in the liver of PHanov animals, suggesting that this group could be more sensitive 363 
to hepatic steatosis. We also found that the levels of the PPARs coactivator, Pgc1a, a 364 
key regulator of lipid metabolism, were decreased in both PH groups as compared with 365 
the control group. In fact, PGC1a not only acts as a regulator of PPARs but also 366 
promotes oxidation of fatty acids by binding to specific transcription factors, modulates 367 
mitochondrial functions, and controls glucose homeostasis (Fernandez-Marcos and 368 
Auwerx 2011; Liang and Ward 2006). Taken together, our data suggest that 369 
dysregulation of lipogenesis and fatty acid oxidation could lead in the long-term to the 370 
development of hepatic damage, deepened by decreased insulin sensitivity.  371 
Oxidative stress and the pro-inflammatory process are also involved in the pathogenesis 372 
of hepatic damage. Oxidative stress is involved in the regulation of very low-density 373 
lipoprotein (VLDL) production and its excretion by the liver (Pan, et al. 2004).  374 
Moreover, the addition of GSH to rat hepatoma cells reverses steatosis and decreases 375 
lipid peroxidation levels (Pan et al. 2004). In the liver, GSH levels correlate with high 376 
levels of circulating LDL cholesterol, which reinforces the association between the 377 
oxidative balance and lipid metabolism (Lin et al. 2014). In agreement with these 378 
findings, here we found that GSH compensated the damage caused by lipid peroxidation 379 
in the PHov group but not in the PHanov group. We suggest that in the PHov group 380 
GSH could be modulating VLDL secretion from the liver to the circulation, as 381 
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manifested by the increased levels of serum LDL observed, and thus preventing the 382 
accumulation of VLDL, as evidenced by the lack of accumulation of lipid droplets. 383 
As mentioned before, the pro-inflammatory process is involved in the development of 384 
NAFLD (Day and James 1998) and prostaglandins and COX2 play a role in lipid 385 
metabolism and lipid accumulation in the liver (Hsieh, et al. 2009; Ii, et al. 2009; Yu, et 386 
al. 2006). Increased levels of PGE correlate with TG accumulation in the liver (Henkel, 387 
et al. 2012; Hsieh et al. 2009; Ii et al. 2009). In agreement with these data, we found that 388 
decreased levels of PGE and COX2 in the PH groups evidenced an alteration in the pro-389 
inflammatory mediators that could be preventing liver fat accumulation. In fact, the 390 
decrease in the inflammatory pathway in the PH groups correlated with a lack of 391 
increase in TG content. These results contribute to the explanation of the absence of 392 
lipid droplets in the PHanov group. Although the liver PPAR system was altered and 393 
lipogenesis was favored, there was a systemic manifestation of these consequences seen 394 
by an altered circulating lipid profile. Thus, a depletion of the pro-inflammatory 395 
mediators could be acting as a compensatory system.   396 
Hepatic transaminases have been described as markers of liver function and damage 397 
(Vassilatou 2014). Although ALT is one of the hepatic enzymes most used as a marker 398 
to detect hepatic injury, several studies have shown other causes for its increase, 399 
including growth spurs and looming diabetes (Burgert, et al. 2006; Vassilatou 2014). 400 
Despite these findings, it remains controversial whether ALT is a good marker for liver 401 
function because some individuals have NAFLD but normal ALT levels and vice versa 402 
(Kim, et al. 2008). It has been recommended that increased levels of these enzymes in 403 
blood may only be used to detect the inflammation that occurs on the liver due to injury 404 
or damage. Unexpectedly, we found increased levels of ALT only in PHov animals. 405 
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Thus, as the PHanov group presented a great depletion of the pro-inflammatory status, 406 
then ALT serum levels would not be affected in these animals (Burgert et al. 2006; 407 
Kerner, et al. 2005; Yamada, et al. 2006).  408 
It should be pointed out that the incidence of NAFLD and liver fat accumulation are 409 
associated with increasing age and body weight (Michaliszyn, et al. 2013; Park, et al. 410 
2014). Here, we found no alterations in body weight or fatty liver presence related to the 411 
decreased liver inflammation. However, studies are being carried out in adult rats, as we 412 
found that derangements in the metabolic pathway of lipogenesis could worsen through 413 
life (Heber et al. 2013).  414 
Women with the more severe PCOS phenotype show increased prevalence of NAFLD 415 
(Jones, et al. 2012). Here we found that the PHanov group was the most affected, 416 
displaying decreased expression of Pgc1a and Pparalpha and over-expression of 417 
Ppargamma, Srebp, Chrebp, thus being more susceptible to presenting signs of hepatic 418 
steatosis and damage in the long-term (Browning and Horton 2004; Estall, et al. 2009). 419 
Our data are in accordance to the multiple hits hypothesis (Day and James 1998; Lin et 420 
al. 2014) to explain the origins of NAFLD. This involves IR, fatty acid signaling 421 
impairment, oxidative stress and inflammation as contributing factors to NAFLD 422 
development. As we found no lipid accumulation but alterations in the processes 423 
described, steatosis may be a consequence of hepatic signaling derangements and 424 
systemic metabolic detriment. We do not discard that the hepatic alterations found could 425 
be due to an increased testosterone/estradiol ratio, worsened in the PHanov group.  426 
In summary, our data show for the first time that both ovulatory and anovulatory 427 
phenotypes that mimics PCOS features present, at pubertal age, signs of incipient liver 428 
injury and an imbalance of the fatty acid metabolism mediated by the PPAR system, 429 
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SREBP and CHREBP as well as an imbalance of the lipogenic enzymes but without 430 
development of NAFLD. These derangements are related to systemic effects, 431 
dyslipidemia and decreased glucose tolerance.  432 
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Legends of figures 
Figure 1. Prenatally hyperandrogenized murine model. Prenatal hyperandrogenism 
in female offspring of control (Ctl) and prenatally hyperandrogenized (PH) groups. (A) 
Serum testosterone levels. Each column represents the mean + SEM from fifteen 
different animals per group, a vs b p<0.01 by ANOVA test. (B) Serum estradiol levels. 
Each column represents the mean + SEM from fifteen different animals per group, a vs 
b p<0.05 by ANOVA test. (C) A representative ovarian tissue section from the Ctl 
group (40X). (D) A representative ovarian tissue section from the PHov group (40X). 
(E) A representative ovarian tissue section from the PHanov group (40X). (F) Detail of 
a representative ovarian cyst from the PH groups (100X). Corpus luteum (CL), antral 
follicle (AF), cyst (Cy), granulosa cells (GC), theca cells (ThC) and preantral follicles 
(PaF).  
Figure 2. Effects of prenatal hyperandrogenism on liver transaminase levels and 
lipid content. (A) Serum levels of ALT and (B) AST. (C) GGT. Each column 
represents the mean + SEM of control (Ctl) and prenatally hyperandrogenized (PH) 
groups; a vs b p<0.05, by ANOVA test. Liver lipid content was quantified by SUDAN 
IV staining. (D) The cytoplasmic lipid droplets are shown in red, as shown in the 
positive control of the technique (arrows).  Each photo shows the detail (100X) of a 
representative staining of the Ctl group (E) and PHov (F) and PHanov groups (G). 
There was no evidence of cytoplasmic lipid accumulation.  (H) TG content in the liver. 
No significant differences were found between the Ctl and PH groups (p>0.05, by 
ANOVA test). 
Figure 3. Effects of prenatal hyperandrogenism on liver lipid metabolism 
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 The graphs correspond to the mRNA abundance of the gene of interest relative to L32 
mRNA levels of control (Ctl) and prenatally hyperandrogenized (PH) groups. L32 was 
validated as a reference gene using Cts (cycle threshold) (Control=21.76 + 0.24; PHov= 
21.36 + 0.30; PHanov= 21.70 + 0.34; p=0.67) (A) Gene expression of Ppargamma (a vs 
b p<0.01), (B) Srebp (a vs b p<0.05) (C) Chrebp (a vs b p<0.05), (D) Acaca (a vs b 
p<0.01), (E) Acacb (a vs b p<0.01), (F) Fas (a vs b p<0.01), (G) Scd1 (a vs b p<0.05), 
(H) Pparalpha (a vs b p<0.01), and (I) Pgc1a (a vs b p<0.01). Each column represents 
the mean + SEM. Statistical analyses were made by ANOVA test. 
Figure 4. Effects of prenatal hyperandrogenism on liver oxidant/antioxidant 
balance and proinflammatory status. The oxidant–antioxidant balance in liver tissue 
was evaluated by measuring the lipid peroxidation index (A) and the content of the 
antioxidant glutathione (B). Each column represents the mean + SEM. Different letters 
mean statistical significant differences (a≠b≠c, p<0.05 in both cases, by ANOVA test). 
(C) Liver PGE content was measured to evaluate the pro-inflammatory status (a≠b≠c, 
p<0.01 by ANOVA). (D) To evaluate whether PGE levels were influenced by the 
limiting enzyme of its synthesis, COX2 was measured, a vs b p<0.05, by ANOVA test. 
Each column represents the mean + SEM.  
Figure 5. Prenatal hyperandrogenism and metabolic derangements. Metabolic  
features evaluated in female offspring of control (Ctl) and prenatally hyperandrogenized 
(PH) groups. (A) The curve represents the mean growth rates of the Ctl and PH groups. 
Differences between growth rates were not significant (p>0.05, by ANOVA test). (B) 
Basal insulin levels, a vs b p<0.05. (C) Basal glucose levels a vs b p<0.05. (D) Blood 
samples followed by intraperitoneal injection of 2 g dextrose/kg body weight were 
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collected at 0, 30, 60, 90 and 120 minutes post-injection for IPGTT. (E) HOMA-IR 
index a vs b p<0.05. Values are mean + SEM by ANOVA test.  
Figure 6. Effect of prenatal hyperandrogenism on the circulating lipid profile. (A) 
Serum levels of low-density lipoprotein cholesterol (LDL-cholesterol), (B) 
triglycerides, (C) total cholesterol and (D) high-density lipoprotein cholesterol (HDL-
cholesterol). Each column represents the mean + SEM of control (Ctl) and prenatally 
hyperandrogenized (PH) groups; a vs b p<0.01 panel A; p< 0.05 panel B. Data were 
analyzed by ANOVA test.   
Figure 7. Mediators of hepatic lipogenesis and β-oxidation. SREBP, ChREBP and 
PPARgamma are transcription factors involved in the regulation of hepatic lipogenesis. 
Insulin and glucose modulate SREBP and ChREBP, respectively. These transcription 
factors and PPARgamma positively regulate de novo lipogenesis by modulating the 
expression of the enzymes involved in this pathway. On the other hand, PPARalpha and 
PGC1a are positively regulators of genes involved in fatty acid oxidation. A balance 
between these processes is needed to avoid hepatic liver accumulation leading to 
steatosis. Insulin resistance is associated with an increase in lipogenesis due to an up-
regulation of ChREBP, SREBP-1c and PPARgamma and a decrease in fatty acid 
oxidation due to a negative regulation on PPARalpha.  
 
 
Page 27 of 35
Primers used in real-time PCR 
Gene Primers sequences  Temperature 
of melting(°C) 
Ppargamma F 
Ppargamma R 
5'-TTTTCAAGGGTGCCAGTTTC-3' 
5'-GAGGCCAGCATGGTGTAGAT-3' 
60 
Srebp F  
Srebp R  
5'- TAACCTGGCTGAGTGTGCAG -3' 
5'- ATCCACGAAGAAACGGTGAC -3' 
60 
Chrebp F 
Chrebp R 
5'- GGTTGTCCCCAAAGCAGAGA -3' 
5'- TTGTTGTCTACACGACCCCG -3' 
62 
Acaca F 
Acaca R 
5'-CCAGACCCTTTCTTCAGCAG-3' 
5'-AGGACCGATGTGATGTTGCT-3' 
62 
AcacbF  
Acacb R  
5'-CAAAGCCTCTGAAGGTGGAG-3' 
5'- CTCGTCCAAACAGGGACACT -3' 
62 
Fas F  
Fas R  
5'-TCGAGACACATCGTTTGAGC-3' 
5'-CCCAGAGGGTGGTTGTTAGA-3' 
62 
Scd1F  
Scd1 R  
5'-GCTTCCAGATCCTCCCTACC-3' 
5'-CAACAACCAACCCTCTCGTT-3' 
62 
Pparalpha F 
Pparalpha R 
5'-TCACACGATGCAATCCGTTT-3' 
5'-GGCCTTGACCTTGTTCATGT-3' 
60 
Pgc1a F  
Pgc1a R  
5'-AATGCAGCGGTCTTAGCACT-3' 
5'-GTGTGAGGAGGGTCATCGTT-3' 
60 
L32 F  
L32 R  
5'-TGGTCCACAATGTCAAGG-3'  
5'-CAAAACAGGCACACAAGC-3' 
58 
 
Table 1 :List of primers used in real-time PCR. (F) forward sequence, (R) reverse sequence. 
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Figure 1. Prenatally hyperandrogenized murine model. Prenatal hyperandrogenism in female offspring of 
control (Ctl) and prenatally hyperandrogenized (PH) groups. (A) Serum testosterone levels. Each column 
represents the mean + SEM from fifteen different animals per group, a vs b p<0.01 by ANOVA test. (B) 
Serum estradiol levels. Each column represents the mean + SEM from fifteen different animals per group, a 
vs b p<0.05 by ANOVA test. (C) A representative ovarian tissue section from the Ctl group (40X). (D) A 
representative ovarian tissue section from the PHov group (40X). (E) A representative ovarian tissue section 
from the PHanov group (40X). (F) Detail of a representative ovarian cyst from the PH groups (100X). Corpus 
luteum (CL), antral follicle (AF), cyst (Cy), granulosa cells (GC), theca cells (ThC) and preantral follicles 
(PaF).  
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Figure 2. Effects of prenatal hyperandrogenism on liver transaminase levels and lipid content. (A) Serum 
levels of ALT and (B) AST. (C) GGT. Each column represents the mean + SEM of control (Ctl) and prenatally 
hyperandrogenized (PH) groups; a vs b p<0.05, by ANOVA test. Liver lipid content was quantified by SUDAN 
IV staining. (D) The cytoplasmic lipid droplets are shown in red, as shown in the positive control of the 
technique (arrows).  Each photo shows the detail (100X) of a representative staining of the Ctl group (E) 
and PHov (F) and PHanov groups (G). There was no evidence of cytoplasmic lipid accumulation.  (H) TG 
content in the liver. No significant differences were found between the Ctl and PH groups (p>0.05, by 
ANOVA test).  
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Figure 3. Effects of prenatal hyperandrogenism on liver lipid metabolism  
The graphs correspond to the mRNA abundance of the gene of interest relative to L32 mRNA levels of 
control (Ctl) and prenatally hyperandrogenized (PH) groups. L32 was validated as a reference gene using 
Cts (cycle threshold) (Control=21.76 + 0.24; PHov= 21.36 + 0.30; PHanov= 21.70 + 0.34; p=0.67) (A) 
Gene expression of Ppargamma (a vs b p<0.01), (B) Srebp (a vs b p<0.05) (C) Chrebp (a vs b p<0.05), (D) 
Acaca (a vs b p<0.01), (E) Acacb (a vs b p<0.01), (F) Fas (a vs b p<0.01), (G) Scd1 (a vs b p<0.05), (H) 
Pparalpha (a vs b p<0.01), and (I) Pgc1a (a vs b p<0.01). Each column represents the mean + SEM. 
Statistical analyses were made by ANOVA test.  
 
254x228mm (300 x 300 DPI)  
 
 
Page 31 of 35
  
 
 
Figure 4. Effects of prenatal hyperandrogenism on liver oxidant/antioxidant balance and proinflammatory 
status. The oxidant–antioxidant balance in liver tissue was evaluated by measuring the lipid peroxidation 
index (A) and the content of the antioxidant glutathione (B). Each column represents the mean + SEM. 
Different letters mean statistical significant differences (a≠b≠c, p<0.05 in both cases, by ANOVA test). (C) 
Liver PGE content was measured to evaluate the pro-inflammatory status (a≠b≠c, p<0.01 by ANOVA). (D) 
To evaluate whether PGE levels were influenced by the limiting enzyme of its synthesis, COX2 was 
measured, a vs b p<0.05, by ANOVA test. Each column represents the mean + SEM.  
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Figure 5. Prenatal hyperandrogenism and metabolic derangements. Metabolic  features evaluated in female 
offspring of control (Ctl) and prenatally hyperandrogenized (PH) groups. (A) The curve represents the mean 
growth rates of the Ctl and PH groups. Differences between growth rates were not significant (p>0.05, by 
ANOVA test). (B) Basal insulin levels, a vs b p<0.05. (C) Basal glucose levels a vs b p<0.05. (D) Blood 
samples followed by intraperitoneal injection of 2 g dextrose/kg body weight were collected at 0, 30, 60, 90 
and 120 minutes post-injection for IPGTT. (E) HOMA-IR index a vs b p<0.05. Values are mean + SEM by 
ANOVA test.  
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Figure 6. Effect of prenatal hyperandrogenism on the circulating lipid profile. (A) Serum levels of low-density 
lipoprotein cholesterol (LDL-cholesterol), (B) triglycerides, (C) total cholesterol and (D) high-density 
lipoprotein cholesterol (HDL-cholesterol). Each column represents the mean + SEM of control (Ctl) and 
prenatally hyperandrogenized (PH) groups; a vs b p<0.01 panel A; p< 0.05 panel B. Data were analyzed by 
ANOVA test.    
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Figure 7. Mediators of hepatic lipogenesis and β-oxidation. SREBP, ChREBP and PPARgamma are 
transcription factors involved in the regulation of hepatic lipogenesis. Insulin and glucose modulate SREBP 
and ChREBP, respectively. These transcription factors and PPARgamma positively regulate de novo 
lipogenesis by modulating the expression of the enzymes involved in this pathway. On the other hand, 
PPARalpha and PGC1a are positively regulators of genes involved in fatty acid oxidation. A balance between 
these processes is needed to avoid hepatic liver accumulation leading to steatosis. Insulin resistance is 
associated with an increase in lipogenesis due to an up-regulation of ChREBP, SREBP-1c and PPARgamma 
and a decrease in fatty acid oxidation due to a negative regulation on PPARalpha.  
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